Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 2/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 2/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
| ▸ | MTOR | P42345 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30349636 | 1.00 | ADORA2B (0.42) | ADORA2BPDE4BTDP1HSD17B10POLB | |
| SCHEMBL25408350 | 0.90 | ADORA2B (0.47) | ADORA2BPDE4BHSD17B10HPGDHTT | |
| SCHEMBL30349777 | 0.90 | ADORA2B (0.47) | ADORA2BPDE4BHSD17B10HPGDHTT | |
| SCHEMBL25407320 | 0.89 | HSD17B10 (0.46) | ADORA2BHSD17B10GSK3BHPGDHTT | |
| SCHEMBL30349827 | 0.83 | KDM4E (0.41) | ADORA2BPDE4BADORA2A | |
| SCHEMBL30349743 | 0.83 | ALDH1A1 (0.44) | ADORA2BPDE4BADORA2A | |
| SCHEMBL25408308 | 0.83 | ALDH1A1 (0.44) | ADORA2BPDE4BADORA2A | |
| SCHEMBL25406873 | 0.83 | KDM4E (0.41) | ADORA2BPDE4BADORA2A | |
| SCHEMBL25436149 | 0.81 | PRKDC (0.38) | ADORA2BPDE4BATMPIK3CAMTOR | |
| SCHEMBL30349870 | 0.81 | PRKDC (0.38) | ADORA2BPDE4BATMPIK3CAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590066-B2 | Fused-heterocyclyl-carbonohydrazonoyl dicyanide compounds and use thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2026-03-31 | — | — | US | disclosed |
| US-20230295095-A1 | NOVEL FUSED-HETEROCYCLYL-CARBONOHYDRAZONOYL DICYANIDE COMPOUNDS AND USE THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2023-09-21 | — | — | US | disclosed |
| EP-4169905-A1 | NOVEL FUSED HETEROCYCLIC CARBONOHYDRAZONOYL DICYANIDE COMPOUND AND USE THEREOF | Korea Institute of Science and Technology (KR) | 2023-04-26 | — | — | EP | disclosed |
| CN-115867277-A | Novel fused heterocyclyl-carbohydrazone acyldinitrile compounds and use thereof | 韩国科学技术研究院 | 2023-03-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12590066-B2 | Fused-heterocyclyl-carbonohydrazonoyl dicyanide compounds and use thereof | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1, CLIC1 | ADORA2B 1863/4885PDE4B 3150/4885TDP1 2103/4885 |
| US-20230295095-A1 | NOVEL FUSED-HETEROCYCLYL-CARBONOHYDRAZONOYL DICYANIDE COMPOUNDS AND USE THEREOF | CBR3, DBF4, DDT | ADORA2B 3600/4885PDE4B 2231/4885TDP1 2868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.